BACKGROUND: Radioiodine is efficiently concentrated by tissues expressing the human sodium iodide symporter (hNIS). OBJECTIVE: To analyze the effects of iodine 131 on acute cardiac allograft rejection after ex vivo hNIS gene transfer in a rat model of cardiac allotransplantation. MATERIALS AND METHODS: Hearts from Brown Norway rats were perfused ex vivo either with UW (University of Wisconsin) solution (n = 9) or UW solution containing 1 x 10(9) pfu/mL of adenovirus 5 plus NIS (Ad-NIS) (n = 18). Donor hearts were transplanted heterotopically into the abdomen of Lewis rats, and recipients were treated on postoperative day 3 with either 15,000 microCi of (131)I or saline solution. The hearts were explanted when no longer beating, and were evaluated histologically for evidence of rejection and other changes. RESULTS: Grafts perfused with the Ad-NIS vector survived significantly longer in recipients injected with (131)I (mean [SD], 11.3 [1.9] days) compared with control animals not treated with (131)I (5.7 [0.65] days) (P < .001). Treatment with (131)I did not prolong graft survival in recipients of hearts that were not perfused with Ad-NIS (5.5 [1.0] vs 5.3 [0.8] days). In Ad-NIS (131)I-treated transplants, the level of myocardial damage on day 6 after surgery, when control hearts were rejected, was significantly lower (60.8 [28.0] vs 99.7 [0.8]; P < .05). CONCLUSION: Our findings indicate that (131)I, after NIS gene transfer, can effectively prolong cardiac allograft survival. To our knowledge, this is the first report of the use of NIS-targeted (131)I therapy in cardiac transplantation. Further studies are required to determine the mechanism of this effect and its potential for clinical application.
BACKGROUND:Radioiodine is efficiently concentrated by tissues expressing the humansodium iodide symporter (hNIS). OBJECTIVE: To analyze the effects of iodine 131 on acute cardiac allograft rejection after ex vivo hNIS gene transfer in a rat model of cardiac allotransplantation. MATERIALS AND METHODS: Hearts from Brown Norway rats were perfused ex vivo either with UW (University of Wisconsin) solution (n = 9) or UW solution containing 1 x 10(9) pfu/mL of adenovirus 5 plus NIS (Ad-NIS) (n = 18). Donor hearts were transplanted heterotopically into the abdomen of Lewis rats, and recipients were treated on postoperative day 3 with either 15,000 microCi of (131)I or saline solution. The hearts were explanted when no longer beating, and were evaluated histologically for evidence of rejection and other changes. RESULTS: Grafts perfused with the Ad-NIS vector survived significantly longer in recipients injected with (131)I (mean [SD], 11.3 [1.9] days) compared with control animals not treated with (131)I (5.7 [0.65] days) (P < .001). Treatment with (131)I did not prolong graft survival in recipients of hearts that were not perfused with Ad-NIS (5.5 [1.0] vs 5.3 [0.8] days). In Ad-NIS (131)I-treated transplants, the level of myocardial damage on day 6 after surgery, when control hearts were rejected, was significantly lower (60.8 [28.0] vs 99.7 [0.8]; P < .05). CONCLUSION: Our findings indicate that (131)I, after NIS gene transfer, can effectively prolong cardiac allograft survival. To our knowledge, this is the first report of the use of NIS-targeted (131)I therapy in cardiac transplantation. Further studies are required to determine the mechanism of this effect and its potential for clinical application.
Authors: Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham Journal: J Heart Lung Transplant Date: 2005-06-20 Impact factor: 10.247
Authors: R W Howell; B W Wessels; R Loevinger; E E Watson; W E Bolch; A B Brill; N D Charkes; D R Fisher; M T Hays; J S Robertson; J A Siegel; S R Thomas Journal: J Nucl Med Date: 1999-01 Impact factor: 10.057
Authors: Roisin M Dwyer; Elizabeth R Bergert; Michael K O'Connor; Sandra J Gendler; John C Morris Journal: Hum Gene Ther Date: 2006-06 Impact factor: 5.695
Authors: Ekaterina Dadachova; Andrew Nguyen; Elaine Y Lin; Leo Gnatovskiy; Ping Lu; Jeffrey W Pollard Journal: Nucl Med Biol Date: 2005-10 Impact factor: 2.408
Authors: Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai Journal: Mol Ther Date: 2006-05-19 Impact factor: 11.454
Authors: Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; Claire E Bender; Bradley J Kemp; Val J Lowe; Tanya L Hoskin; Stephen J Russell Journal: Mol Imaging Biol Date: 2006 Nov-Dec Impact factor: 3.484
Authors: Chad W Schmiedt; Robert M Gogal; Stephen B Harvey; Amanda K Torres; Carla L Jarrett; Elizabeth W Uhl; David J Hurley Journal: Comp Med Date: 2011-04 Impact factor: 0.982
Authors: Hirofumi Saiki; Gilles Moulay; Adam J Guenzel; Weibin Liu; Teresa D Decklever; Kelly L Classic; Linh Pham; Horng H Chen; John C Burnett; Stephen J Russell; Margaret M Redfield Journal: Am J Physiol Heart Circ Physiol Date: 2017-05-26 Impact factor: 4.733